Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Melanoma 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 9Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 8Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasm Metastasis 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Cholangiocarcinoma 3Solid Tumor 2Recurrence 2Lymphoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Upper Tract Urinary Carcinoma 1Thyroid Neoplasms 1Thymic epithelial tumor 1

Interventions

toripalimab 1sintilimab 1raltitrexed 1Fluorouracil 1Cisplatin 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Head and Neck Squamous Cell Cancer × toripalimab × Clear all
NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Shanghai Junshi Bioscience Co., Ltd.

Phase 1/2 Unknown
88 enrolled
Head & Neck

Head and Neck Squamous Cell Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡